Immuneering director buys IMRX shares via LLC

Immuneering Corp director Peter Feinberg reported an indirect purchase of Class A common stock on January 12, 2026.

Rhea-AI Filing Summary

Immuneering Corp director Peter Feinberg reported an indirect purchase of Class A common stock on January 12, 2026. Through S4K Investments LLC, he acquired 20,000 shares at a weighted average price of $4.3452 per share, with individual trade prices ranging from $4.315 to $4.38.

After this transaction, Feinberg beneficially owned 135,441 Class A shares indirectly as general partner of S4K Investments LLC. He also held 156,766 shares directly, plus indirect holdings of 392,242 shares as general partner of PF Associates L.P. and 476,615 shares as general partner of PEF LLC.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 4 txns

Insider Feinberg Peter

Role Director

Bought 20,000 shs ($87K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	20,000	$4.3452	$87K
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 135,441 shares (Indirect, General Partner of S4K Investments LLC.); Class A Common Stock — 156,766 shares (Direct); Class A Common Stock — 392,242 shares (Indirect, General Partner of PF Associates L.P.); Class A Common Stock — 476,615 shares (Indirect, General Partner of PEF LLC.)

Footnotes (1)

1. F1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.315 to $4.38. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IMRX director Peter Feinberg report?

Peter Feinberg reported an indirect purchase of 20,000 shares of Immuneering Corp Class A common stock on January 12, 2026, coded as a P (open-market or private purchase) transaction.

What price did S4K Investments LLC pay for the IMRX shares?

The shares were bought at a weighted average price of $4.3452 per share, with individual trades executed between $4.315 and $4.38 through a broker-dealer.

How many IMRX shares does Peter Feinberg beneficially own after the transaction?

Following the reported trade, Feinberg beneficially owned 156,766 Class A shares directly and, indirectly, 135,441 through S4K Investments LLC, 392,242 through PF Associates L.P., and 476,615 through PEF LLC.

How is the S4K Investments LLC ownership reported for IMRX?

Shares held by S4K Investments LLC are reported as indirectly owned by Peter Feinberg in his capacity as general partner of that entity, totaling 135,441 shares after the purchase.

What is Peter Feinberg’s relationship to Immuneering Corp (IMRX)?

Peter Feinberg is reported as a director of Immuneering Corp and is not listed as an officer or 10% owner in this filing.

Were there any derivative securities reported in this IMRX Form 4?

No derivative securities are reported as acquired or disposed of; the table for derivative securities does not list any transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/14/2026 - 08:10 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feinberg Peter

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock								156,766	D
Class A Common Stock								392,242	I	General Partner of PF Associates L.P.
Class A Common Stock								476,615	I	General Partner of PEF LLC.
Class A Common Stock	01/12/2026		P		20,000	A	$4.3452(1)	135,441	I	General Partner of S4K Investments LLC.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.315 to $4.38. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Peter Feinberg	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.